CY2460B1 - Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors. - Google Patents

Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors.

Info

Publication number
CY2460B1
CY2460B1 CY0400048A CY0400048A CY2460B1 CY 2460 B1 CY2460 B1 CY 2460B1 CY 0400048 A CY0400048 A CY 0400048A CY 0400048 A CY0400048 A CY 0400048A CY 2460 B1 CY2460 B1 CY 2460B1
Authority
CY
Cyprus
Prior art keywords
proton pump
oral pharmaceutical
reversible proton
pharmaceutical compositions
delayed release
Prior art date
Application number
CY0400048A
Other languages
English (en)
Inventor
Rango Dietrich
George Sachs
Stefan Postius
Hartmut Ney
Joerg Senn-Bilfinger
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of CY2460B1 publication Critical patent/CY2460B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
CY0400048A 1995-07-05 2004-06-11 Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors. CY2460B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/498,391 US6132768A (en) 1995-07-05 1995-07-05 Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors

Publications (1)

Publication Number Publication Date
CY2460B1 true CY2460B1 (en) 2005-06-03

Family

ID=23980899

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400048A CY2460B1 (en) 1995-07-05 2004-06-11 Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors.

Country Status (11)

Country Link
US (1) US6132768A (cg-RX-API-DMAC7.html)
EP (1) EP0841904B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11508578A (cg-RX-API-DMAC7.html)
AT (1) ATE232091T1 (cg-RX-API-DMAC7.html)
AU (1) AU711577B2 (cg-RX-API-DMAC7.html)
CY (1) CY2460B1 (cg-RX-API-DMAC7.html)
DE (1) DE69626117T2 (cg-RX-API-DMAC7.html)
DK (1) DK0841904T3 (cg-RX-API-DMAC7.html)
ES (1) ES2192227T3 (cg-RX-API-DMAC7.html)
PT (1) PT841904E (cg-RX-API-DMAC7.html)
WO (1) WO1997002021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6331181B1 (en) 1998-12-08 2001-12-18 Intuitive Surgical, Inc. Surgical robotic tools, data architecture, and use
ES2237809T3 (es) * 1997-02-28 2005-08-01 Kaneka Corporation Medicina curativa para la enfermedad causada por infeccion de helicobacter.
WO1999004816A1 (en) * 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
IN186245B (cg-RX-API-DMAC7.html) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SK10272000A3 (sk) * 1998-01-16 2001-01-18 Takeda Chemical Industries, Ltd. Prostriedok s trvalým uvoľňovaním, spôsob jeho výroby a jeho použitia
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
CA2362930C (en) * 1999-02-26 2010-10-05 Nitromed, Inc. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6248718B1 (en) 1999-08-18 2001-06-19 Atlantic Biomed Corporation Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ATE306940T1 (de) * 2000-12-04 2005-11-15 New Pharma Res Sweden Ab Zusammensetzung gegen coccidiose
ATE529097T1 (de) * 2000-12-07 2011-11-15 Nycomed Gmbh Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10145457A1 (de) * 2001-09-14 2003-04-03 Basf Ag Substituierte Imidazo[1,2-a]-5,6,7,8-tetrahydropyridin-8-one, Verfahren zu ihrer Herstellung, sowie deren Verwendung zur Herstellung von Imidazo[1,2,-a]pyridinen
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
EP1534278A4 (en) 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
BR0300882A (pt) * 2003-04-09 2005-05-10 Cmax Otimizacao De Resultados Composições farmacêuticas, método e uso de formulação para tratamento e prevenção de infecções associadas com helicobacter pylori em mamìferos e no ser humano
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
KR100581967B1 (ko) * 2003-12-18 2006-05-22 한국유나이티드제약 주식회사 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
WO2006037766A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
EP1803450A1 (en) 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
CN1857220B (zh) * 2006-04-04 2010-10-06 济南康泉医药科技有限公司 一种抗结核病药物缓释剂
DK2007362T3 (en) 2006-04-04 2018-11-26 Kg Acquisition Llc ORAL DOSAGE FORMS, INCLUDING AN ANTITHROMOBOCYTY AGENT AND AN ACID INHIBITOR
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AU2007278986B2 (en) * 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
EP2152263A1 (en) * 2007-06-07 2010-02-17 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
JP2012502015A (ja) 2008-09-09 2012-01-26 アストラゼネカ・アクチエボラーグ 必要がある患者に医薬組成物を送達するための方法
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20130096123A1 (en) * 2010-04-14 2013-04-18 Eupharma Pty Ltd Radiation sensitiser compositions
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CN110366415A (zh) * 2017-10-15 2019-10-22 消化系统疾病中心 用于治疗、减轻和预防幽门螺杆菌感染的组合物和方法
WO2025067633A1 (en) 2023-09-26 2025-04-03 Amyra Biotech Ag Pharmaceutical compositions comprising aminopeptidase and dipeptidylpeptidase polypeptides and uses thereof
WO2025067635A1 (en) 2023-09-26 2025-04-03 Amyra Biotech Ag Pharmaceutical compositions comprising exopeptidases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3456049A (en) * 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US4464372A (en) * 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
WO1989003219A1 (en) * 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
IL108520A (en) * 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
ES2192227T3 (es) 2003-10-01
DK0841904T3 (da) 2003-05-26
PT841904E (pt) 2003-06-30
EP0841904A1 (en) 1998-05-20
DE69626117D1 (de) 2003-03-13
US6132768A (en) 2000-10-17
HK1010835A1 (en) 1999-07-02
AU6517596A (en) 1997-02-05
AU711577B2 (en) 1999-10-14
JPH11508578A (ja) 1999-07-27
ATE232091T1 (de) 2003-02-15
DE69626117T2 (de) 2003-10-30
EP0841904B1 (en) 2003-02-05
WO1997002021A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
CY2460B1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors.
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
YU36600A (sh) Oralni farmaceutski oblik za doziranje sa pulsnim oslobađanjem
CA2199778A1 (en) Extended release formulation of venlafaxine
PT1003486E (pt) Composicoes farmaceuticas contendo um par acido-base efervescente
MY125766A (en) Flash-melt oral dosage formulation
GR3024561T3 (en) Stable, ingestable and absorbable nadh and nadph therapeutic compositions
AU7239996A (en) Inhibition of tumor necrosis factor alpha
UA27058C2 (uk) Фармацевтичhа композиція, що призhачеhа для одержаhhя порошків або шипучих таблеток, яка містить ефективhу кількість ібупрофеhу, фармацевтичhий препарат hа її осhові та спосіб його одержаhhя
BG106927A (en) Matrix tablet for prolonged release of trimetazidine after oral administration
NZ504460A (en) Sustained release formulations containing venlafaxine
AU2697100A (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
CA2225628A1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
AU4929400A (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
MXPA03005384A (es) Composiciones framaceuticas de un inhibidor de bomba de proton revestido no enterico con una combinacion de sal de bicarbonato y sal de carbonato.
AU3903701A (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
WO2004056353A3 (en) Device and method for delivering mmp inhibitors
SI0841904T1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors